Company Introduction

Company introduction

ISU’s excellent bio-technology expertise provides a global and local potential partner with (1) the
higher productivity at CMO level (2-5g/L), (2) development management system enabling the first-
in-human IND from the cell line development within 24 months, and (3) higher biosimilarity to its
ISU Abxis Co., Ltd. original product.

Products
Product Details
- Indication: Adjunct to Percutaneous Coronary Intervention (PCI)
Accumulation of High-value Core Technologies in - The first therapeutic antibody developed in Korea and the
Biotechnology to Develop Future Products Clotinab (Abciximab) world’s second Abciximab
- Launched in Korea in 2007 and exported to twelve countries
ISU Abxis is the leading Korean biopharmaceutical company which including India, Turkey, Columbia, Venezuela and etc.
succeeds in development on the first therapeutic antibody in Korea. ISU - ‌Indication: Enzyme Replacement Therapy (ERT) for Gaucher
Abxis provides the world-class products to MENA and Latin America disease (GD)
region and continues to expand its business portfolio by collaboration - The first drug for GD developed in Korea and the world’s
with the US and EU based pharmaceutical companies. Abcertin (Imiglucerase)
second Imiglucerase
Since 2001, ISU Abxis has established its own platform technologies - Launcher in Korea in 2013 and under the registration in
and product pipelines with a desire of being an axis of all therapeutic around 20 countries
antibody industry as its name stands (ABXIS=AntiBody + aXIS). Begin-
- Indication: Enzyme Replacement Therapy (ERT) for Fabry disease (FD)
ning with the successful development and market-launch of ISU’s first
Fabagal (Agalsidase - ‌‌The first drug for FD developed in Korea and the world’s second
therapeutic antibody in 2006, ISU Abxis has led Korean biopharmaceu-
beta) Agalsidase beta
tical industry specialized in biosimilars and biobetters. Consequently in
- Launched in Korea in 2014
2013 and 2014, ISU Abxis launched two biotherapeutics for orphan dis-
eases of Gaucher and Fabry. ISU Abxis has accumulated the world class - Indication: adjunctive therapy in the chronic management of
Pheburane (Sodium
manufacturing and QC/QA management through the full development urea cycle disorders
phenylbutyrate)
and manufacturing experiences in the globally harmonized compliance. - Imported product from EU (under the Korean registration)
ISU’s three products, supplied to around 30 countries including Turkey,
India, Algeria and Venezuela, are available as the only alternative R&D Pipeline
against the originator in the world. Furthermore, ISU Abxis operates the
mammalian production dedicated cGMP facility as obtained the GMP
certificates from Turkey, Brazil, Colombia and a number of major coun-
CEO
tries in Latin America and Middle East.
Daeseong Kim
Now ISU Abxis also makes its great efforts in the development of novel
Location biologics for the patients with cancer and hemophilia. Besides the inter-
Global R&D Center C-5F, 22
nal development activities, ISU Abxis recently does its best in importing
Daewangpangyo-ro, 712beon-
gil, Bundang-gu, Seongnam-si, and providing orphan drugs for Korean patients who suffer the lack of
Gyeonggi-do, 13488, Korea treatment option.
Homepage ISU Abxis will grow its advanced technology based business for diffi-
www.abxis.com cult-to-treat and orphan disease market both domestically and world-
wide

40 41